Class IIOngoing

Levothyroxine Sodium Tablets recall

FDA recall D-0136-2025 · initiated Nov 19, 2024

May cause temporary or medically reversible harm; low probability of serious harm.

Why it was recalled

Subpotent and Superpotent Drug

Details

Product: Levothyroxine Sodium Tablets, USP, 175 mcg (0.175 mg), 100 Tablets per carton (10 unit dose blister cards of 10 tablets each), Rx only, Manufactured for: Mylan Pharmaceuticals Inc., Morgantown, WV 26505 USA. NDC: 42292-040-20
Recalling company: Mylan Institutional
Classification: Class II
Status: Ongoing
Type: Voluntary: Firm initiated
Distribution: Nationwide in the USA.
Initiated: Nov 19, 2024
FDA report date: Dec 18, 2024

What to do.If you have a recalled product, don't throw away questions — check the FDA notice for the affected lot numbers and expiration dates, and ask your pharmacist or doctor before stopping a prescribed medicine. This page reproduces public FDA data and is not medical advice.

Source: openFDA Drug Enforcement record D-0136-2025 ↗

← All drug recalls